Results 21 to 30 of about 88,087 (318)

The pharmacogenetics of imanitib [PDF]

Genome Medicine, 2010
Imatinib mesylate (IM), a tyrosine kinase inhibitor, is one of the first molecularly targeted therapies to have been used in the clinic. It has proven to be efficient in the treatment of chronic myeloid leukemia and also in other malignancies that involve expression of a tyrosine kinase.
Stéphanie Dulucq, Maja Krajinovic
openaire   +3 more sources

Pharmacogenetic testing in oncology: a Brazilian perspective

Clinics, 2018
Pharmacogenetics, a major component of individualized or precision medicine, relies on human genetic diversity. The remarkable developments in sequencing technologies have revealed that the number of genetic variants modulating drug action is much higher
Guilherme Suarez-Kurtz
doaj   +1 more source

Context, ethics and pharmacogenetics [PDF]

, 2006
Most of the literature on pharmacogenetics assumes that the main problems in implementing the technology will be institutional ones (due to funding or regulation) and that although it involves genetic testing, the ethical issues involved in ...
Adam M. Hedgecoe, Akhtar, Anderson, Anon, Bazell, Beauchamp, Beeson, Brodaty, Brushwood, Clarke, DeVries, Emery, Ensom, Evans, Farlow, Farrer, Fox, Ginsburg, Haimes, Haseltine, Hedgecoe, Hedgecoe, Hoffmaster, Hoffmaster, Issa, Issa, Jazwinska, Johnson, Kumar, Kumar, Levine, Lindpaintner, Lindpaintner, McConnell, McLeod, Nelson, Noguchi, Nuffield Council on Bioethics., Palmer, Pfost, Poirier, Post, Relkin, Richard, Rioux, Ritchie, Robertson, Roses, Rothstein, Rusnak, Sadee, Saunders, Shi, Smith, Smith, Sugarman, Vaszar, Wolf, Zussman   +58 more
core   +1 more source

Engineering a folic acid-decorated ultrasmall gemcitabine nanocarrier for breast cancer therapy: Dual targeting of tumor cells and tumor-associated macrophages

Acta Pharmaceutica Sinica B, 2022
Combination of passive targeting with active targeting is a promising approach to improve the therapeutic efficacy of nanotherapy. However, most reported polymeric systems have sizes above 100 nm, which limits effective extravasation into tumors that are
Pearl Moharil, Zhuoya Wan, Apurva Pardeshi, Jiang Li, Haozhe Huang, Zhangyi Luo, Sanjay Rathod, Ziqian Zhang, Yuang Chen, Bei Zhang, Christian A. Fernandez, Jingjing Sun, Song Li   +12 more
doaj   +1 more source

Pharmacogenetics of analgesic drugs [PDF]

, 2013
• Individual variability in pain perception and differences in the efficacy of analgesic drugs are complex phenomena and are partly genetically predetermined.
Branford, R, Cregg, R, Gubbay, A, Russo, G, Sato, H   +4 more
core   +1 more source

Some aspects of genetics and pharmacogenetics understanding by pharmacy students in Ukraine

Egyptian Journal of Medical Human Genetics, 2015
Background: Prescription and administration of drugs are still carried out without taking into consideration the individual’s needs of a particular patient on the post-Soviet territory.
O.V. Filiptsova, M.N. Kobets, Yu.N. Kobets   +2 more
doaj   +1 more source

Standardizing CYP2D6 Genotype to Phenotype Translation: Consensus Recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group

Clinical and Translational Science, 2019
Translating CYP2D6 genotype to metabolizer phenotype is not standardized across clinical laboratories offering pharmacogenetic (PGx) testing and PGx clinical practice guidelines, such as the Clinical Pharmacogenetics Implementation Consortium (CPIC) and ...
K. Caudle, K. Sangkuhl, Michelle Whirl‐Carrillo, J. Swen, Cyrine E. Haidar, T. Klein, Roseann S. Gammal, M. Relling, S. Scott, D. Hertz, H. Guchelaar, A. Gaedigk   +11 more
semanticscholar   +1 more source

Pharmacogenetics at scale: An analysis of the UK Biobank

bioRxiv, 2020
Pharmacogenetics (PGx) studies the influence of genetic variation on drug response. Clinically actionable associations inform guidelines created by the Clinical Pharmacogenetics Implementation Consortium (CPIC), but the broad impact of genetic variation ...
G. McInnes, A. Lavertu, K. Sangkuhl, T. Klein, Michelle Whirl‐Carrillo, R. Altman   +5 more
semanticscholar   +1 more source

From pharmacogenetics to pharmaco-omics: Milestones and future directions

HGG Advances, 2022
The origins of pharmacogenetics date back to the 1950s, when it was established that inter-individual differences in drug response are partially determined by genetic factors.
Chiara Auwerx, Marie C. Sadler, Alexandre Reymond, Zoltán Kutalik   +3 more
doaj   +1 more source

Toward a clinical practice guide in pharmacogenomics testing for functional polymorphisms of drug-metabolizing enzymes. Gene/drug pairs and barriers perceived in Spain [PDF]

, 2012
The development of clinica lpractice recommendations or guidelines for the clinical use of biomarkers is an issue of great importance withr regard to adverse drug reactions.The poten-tial of pharmacogenomicbiomarkers has been extensively investigated in
Abad Santos, Francisco, Aldea, Ana, Alonso-Navarro, Hortensia, Bernal, María Luisa, Borobia, Alberto M., Borràs, Emma, Carballo, Miguel, Carvajal, Alfonso, García-Agúndez, José Augusto, García-Martín, Elena, García-Muñiz, José D., Gervasini, Guillermo, Jiménez-Jiménez, Félix Javier, Lucena, María Isabel, Martínez, Carmen, Sacristán, José A., Salado, Inés, Sinués, Blanca, Vicente, Jorge   +18 more
core   +4 more sources